Background: Based on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia patients is associated with different types of transcript proteins. In this study we have seen the association of HLA genes with different types of bcr-abl transcripts. The association could predict the bcr-abl peptide presentation by particular HLA molecules.
Methods: The study included a total of 189 patients of mixed ethnicity with chronic myelogenous leukemia and acute lymphocytic leukemia who were being considered for bone marrow transplantation. Typing of bcr-abl transcripts was done by reverse transcriptase PCR method. HLA typing was performed by molecular methods. The bcr-abl and HLA association was studied by calculating the relative risks and chi-square test.
Results: Significant negative associations (p < 0.05) were observed with HLA-A*02 (b2a2, e1a2), -A*68 (b2a2, b3a2, e1a2), -B*14 (b2a2, b3a2, e1a2), -B*15 (b2a2, b3a2), -B*40 (b2a2), -DQB1*0303 (b2a2, b3a2), -DQB1*0603 (b2a2), -DRB1*0401 (e1a2), -DRB1*0701 (b3a2), and -DRB1*1101 (b2a2).
Conclusions: The negative associations of a particular bcr-abl transcript with specific HLA alleles suggests that these alleles play a critical role in presenting peptides derived from the chimeric proteins and eliciting a successful T-cell cytotoxic response. Knowledge of differential associations between HLA phenotypes and bcr-abl fusion transcript types would help in developing better strategies for immunization with the bcr-abl peptides against t(9;22) (q34;q11)-positive leukemia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC441382 | PMC |
| http://dx.doi.org/10.1186/1471-2407-4-25 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishment of genomic RNA reference materials for BCR-ABL1 P210 measurement.
Anal Bioanal Chem
November 2024
Center for Advanced Measurement Science, National Institute of Metrology, Beijing, 100029, China.
Quantitation of BCR-ABL1 with the quantitative reverse transcriptase polymerase chain reaction (RT-PCR) is very important in monitoring chronic myeloid leukemia (CML), which relies on an RNA reference material. A genomic RNA reference material (RM) containing the BCR-ABL1 P210 fusion mutation was developed, and an absolute quantitative method based on one-step reverse transcription digital PCR (RT-dPCR) was established for characterizing the RM. The proposed dPCR method demonstrates high accuracy and excellent analytical sensitivity, as shown by the linear relationship (0.
View Article and Find Full Text PDFVariant-specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia.
Int J Lab Hematol
October 2024
Clinical Laboratory, AZ Sint-Lucas Hospital Ghent, Ghent, Belgium.
Article Synopsis
- Accurate measurement of the BCR::ABL1 fusion gene is crucial for managing chronic myeloid leukemia (CML), most commonly found as the p210 variant due to certain mRNA junctions.
- The study analyzed 25 CML samples using two accredited centers with qPCR methods and compared results using advanced techniques like ddPCR, revealing significant differences in measurement accuracy.
- Findings highlight that quantification differences may vary by center, impacting patient follow-up, and suggest that using specific standard curves or absolute quantification methods can mitigate these discrepancies.
Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival.
Genes (Basel)
April 2024
Departamento de Medicina y Nutrición, División Ciencias de la Salud, Universidad de Guanajuato, Campus León, León 37670, Guanajuato, México.
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of the Philadelphia chromosome, a product of the reciprocal translocation t(9;22)(q34;q11), in the BCR and ABL genes. These rearrangements in both genes lead to the formation of various fusion mRNA products, with preferential expression of , , and other mRNA variants, combined with additional chromosomal abnormalities. Notably, the distribution and frequency of different mRNA variants vary in different populations.
View Article and Find Full Text PDFFrequencies of BCR::ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis.
Genes (Basel)
February 2024
Department of Medicine and Nutrition, Division of Health Sciences, University of Guanajuato, Campus León, León 37320, Guanajuato, Mexico.
Chronic myeloid leukemia (CML) is associated with the Philadelphia chromosome and distinct BCR::ABL1 gene transcripts. We assessed the frequencies of these transcripts in Mexico, Latin America, and worldwide. We determined the prevalence of BCR::ABL1 transcripts in CML patients and intercontinental or regional variations using specialized databases and keywords.
View Article and Find Full Text PDFA review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes.
Hematology
December 2023
Microbial Cellular and Molecular Biology Department, Addis Ababa University, Addis Ababa, Ethiopia.
Chronic myeloid leukemia (CML) is a clonal myeloproliferative growth of human pluripotent stem cells which is estimated to occur at a rate of 1/100000 populations every year worldwide. A characteristic feature of this disease is the presence of the Philadelphia chromosome genotype, which results from the reciprocal translocation between human chromosomes 9 and 22. Two types of major genotypes are involved, which consequently result in two major types of expressed fusion mRNA transcripts: b3a2 and b2a2, i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!